Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Add filters

Document Type
Year range
Critical Care Medicine ; 50:96-96, 2022.
Article in English | Academic Search Complete | ID: covidwho-1596378


Many COVID19 patients develop Acute Respiratory Distress Syndrome (ARDS), resulting from an uncontrolled inflammatory response to infection. B Results: b Of the 54 patients treated with colchicine, 8 developed ARDS, while 2 developed ARDS in the control group (14.81% vs 3.70%;I P i =0.05;odds ratio [OR] 4.52 [95% confidence interval {CI} 0.91-22.38]). [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)

Front Med (Lausanne) ; 8: 630209, 2021.
Article in English | MEDLINE | ID: covidwho-1121692


Rationale: Coronavirus disease 2019 (COVID-19) can cause disruption of the renin-angiotensin system in the lungs, possibly contributing to pulmonary capillary leakage. Thus, angiotensin receptor blockers (ARBs) may improve respiratory failure. Objective: Assess safety of losartan for use in respiratory failure related to COVID-19 (NCT04335123). Methods: Single arm, open label trial of losartan in those hospitalized with respiratory failure related to COVID-19. Oral losartan (25 mg daily for 3 days, then 50 mg) was administered from enrollment until day 14 or hospital discharge. A post-hoc external control group with patients who met all inclusion criteria was matched 1:1 to the treatment group using propensity scores for comparison. Measures: Primary outcome was cumulative incidence of any adverse events. Secondary, explorative endpoints included measures of respiratory failure, length of stay and vital status. Results: Of the 34 participants enrolled in the trial, 30 completed the study with a mean age SD of 53.8 ± 17.7 years and 17 males (57%). On losartan, 24/30 (80%) experienced an adverse event as opposed to 29/30 (97%) of controls, with a lower average number of adverse events on losartan relative to control (2.2 vs. 3.3). Using Poisson regression and controlling for age, sex, race, date of enrollment, disease severity at enrollment, and history of high-risk comorbidities, the incidence rate ratio of adverse events on losartan relative to control was 0.69 (95% CI: 0.49-0.97) Conclusions: Losartan appeared safe for COVID-19-related acute respiratory compromise. To assess true efficacy, randomized trials are needed.

J Manuf Syst ; 60: 774-786, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-885346


During the current Pandemic, seven and a half million flights worldwide were canceled which disrupted the supply chain of all types of goods such as, personal protective gears, medical health devices, raw materials, food, and other essential equipments. The demand for health and medical related goods increased during this period globally, while the production using classical manufacturing techniques were effected because of the lockdowns and disruption in the transporation system. This created the need of geo scattered, small, and rapid manufacturing units along with a smart computer aided design (CAD) facility. The availability of 3D printing technologies and open source CAD design made it possible to overcome this need. In this article, we present an extensive review on the utilization of 3D printing technology in the days of pandamic. We observe that 3D printing together with smart CAD design show promise to overcome the disruption caused by the lockdown of classical manufacturing units specially for medical and testing equipment, and protective gears. We observe that there are several short communications, commentaries, correspondences, editorials and mini reviews compiled and published; however, a systematic state-of-the-art review is required to identify the significance of 3D printing, design for additive manufacturing (AM), and digital supply chain for handling emergency situations and in the post-COVID era. We present a review of various benefits of 3DP particularly in emergency situations such as a pandemic. Furthermore, some relevant iterative design and 3DP case studies are discussed systematically. Finally, this article highlights the areas that can help to control the emergency situation such as a pandemic, and critically discusses the research gaps that need further research in order to exploit the full potential of 3DP in pandemic and post-pandemic future era.